

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (currently amended): A skin-care composition containing 20-O- $\beta$ -D-glucopyranosyl-20(S)- protopanaxatriol (ginsenoside F1) and (–)epigallocatechin-3-gallate (EGCG) as active ingredients, wherein the weight ratio of ginsenoside F1: EGCG is in the range of 1:01-1:10; and wherein said ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.
2. (original): The composition according to Claim 1, wherein said skin-care is obtained by the apoptosis-inhibitory effect of said active ingredients.
3. (canceled). ~~The composition according to Claim 2, wherein said apoptosis is apoptotic cell death induced by low dose of UV irradiation~~
4. (currently amended): The composition according to ~~Claims 2 or 3 claim~~ 2, wherein said apoptosis-inhibitory effect is obtained by regulating the expression of Bcl-2.

5. (original): The composition according to Claim 4, wherein said regulation of Bcl-2 expression is obtained by regulating the expression of Brn-3a.

6-7. (canceled).

8. (currently amended): An inhibitor of Rb protein dephosphorylation containing ginsenoside F1 and EGCG as active ingredients, wherein the weight ratio of ginsenoside F1 : EGCG is in the range of 1:0.1 – 1: 10 and wherein said ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.

9. (currently amended): An inhibitor of skin damage for preventing cellular damage caused by exposure to ultraviolet rays, containing a combination of low concentrations of ginsenoside F1 and EGCG as an active ingredient, wherein the weight ratio of ginsenoside F1 : EGCG is in the range of 1:0.1 – 1: 10 and wherein said ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.

10. (currently amended): An external composition for skin care containing a combination of ginsenoside F1 and EGCG as an active ingredient, wherein the weight ratio of ginsenoside F1 : EGCG is in the range of 1:0.1 – 1: 10 and wherein said

ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.

11. (new): The composition according to claim 1, wherein the weight ratio of ginsenoside F1 : EGCG is 1:5.